Multi-Pathway Tissue Research
The KLOW blend combines compounds studied across overlapping tissue remodeling pathways. BPC-157 and TB-500 have each been independently studied for connective tissue and wound biology in rodent models.
Overview
What is KLOW?
KLOW is a proprietary research blend combining four well-characterized peptides: GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg). Each compound in the blend has an independent body of peer-reviewed research. The combination is studied by researchers interested in the concurrent biological activity of these compounds in tissue biology and inflammatory models.
KLOW (KLOW Peptide Blend) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
Investigational Scope
Documented Research Areas
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
Inflammation Modulation
KPV (Lys-Pro-Val) is a C-terminal fragment of alpha-MSH with documented anti-inflammatory properties in cell culture and animal models. Its inclusion alongside BPC-157 provides dual anti-inflammatory research potential.
Collagen & ECM Remodeling
GHK-Cu is the primary ECM-modulating component in the blend, with an extensive literature base documenting collagen I, III, and elastin upregulation in fibroblast cultures.
Synergy & Interaction Studies
Researchers studying multi-compound peptide interactions use the KLOW blend to examine potential additive or synergistic effects across the four included peptides in standardized animal models.
Proposed Mechanism
Mechanistic Pathway
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
-
1
GHK-Cu: Copper Transport & Collagen Synthesis
GHK-Cu delivers bioavailable copper to cells, activating lysyl oxidase for collagen and elastin crosslinking, and modulating TGF-β pathways involved in ECM remodeling.
-
2
BPC-157: VEGF & NO System Interaction
BPC-157 contributes VEGFR2 upregulation and nitric oxide system modulation to the blend, with documented angiogenic activity and fibroblast stimulation in independent rodent studies.
-
3
TB-500: Actin Sequestration & Cell Migration
TB-500 (Thymosin Beta-4 fragment) sequesters G-actin and promotes cell migration and tissue remodeling through actin dynamics modulation, studied independently in wound healing models.
-
4
KPV: Melanocortin Receptor Anti-Inflammatory Activity
KPV acts on melanocortin receptors (MC1R, MC3R) to suppress NF-κB signaling and reduce pro-inflammatory cytokine production in cell culture and mucosal inflammation models.
Technical Data
Molecular Specifications
| Amino Acid Sequence | Blend: GHK-Cu + BPC-157 + TB-500 + KPV |
|---|---|
| Molecular Weight | Multiple compounds |
| Molecular Formula | Multiple compounds |
| CAS Number | Blend — see individual compounds |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
References
Selected Literature
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
- Pickart L & Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences, 19(7), 1987.
- Sikiric P, et al. (2018). Stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 24(18), 1938–1956.
- Goldstein AL, et al. (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(1), 37–51.
- Luger TA & Brzoska T. (2007). Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases, 66(Suppl 3), 52–55.
- Hsieh MJ, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. Journal of Molecular Medicine, 95(3), 323–333.
Research Disclaimer
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.